{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:30:56Z","timestamp":1789115456482,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002838","name":"Changchun Institute of Applied Chemistry, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011501","name":"Qinghai Science and Technology Department","doi-asserted-by":"publisher","award":["2022-ZJ-915"],"award-info":[{"award-number":["2022-ZJ-915"]}],"id":[{"id":"10.13039\/501100011501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tranon.2026.102828","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:36:17Z","timestamp":1780090577000},"page":"102828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combined treatment of TROP\u20112 targeted CAR-T and vascular disruptor CBP enhances anti\u2011tumor activity in triple\u2011negative breast cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Yizhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiSheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuFan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"JiaHu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiYuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiMing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-4884","authenticated-orcid":false,"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tranon.2026.102828_bib0001","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/curroncol33020120","article-title":"Romanian consensus statement for hormone receptor-positive and Human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+\/HER2- mBC) and triple-negative metastatic breast cancer (mTNBC)","volume":"33","author":"Median","year":"2026","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.tranon.2026.102828_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102828_bib0003","article-title":"Recent advances in antibody-drug conjugates and immunotherapy combinations for treatment of triple-negative breast cancer","volume":"18","author":"Chen","year":"2026","journal-title":"Breast. Cancer."},{"key":"10.1016\/j.tranon.2026.102828_bib0004","article-title":"The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"10272","key":"10.1016\/j.tranon.2026.102828_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(21)00001-5","article-title":"National institute for health research global health research unit on global S. global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries","volume":"397","author":"GlobalSurg","year":"2021","journal-title":"Lancet"},{"issue":"S1","key":"10.1016\/j.tranon.2026.102828_bib0006","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102828_bib0007","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunther."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer."},{"issue":"12","key":"10.1016\/j.tranon.2026.102828_bib0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102828_bib0011","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","article-title":"Metabolic regulation of macrophage polarization in cancer","volume":"5","author":"Mehla","year":"2019","journal-title":"Trends. Cancer."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Heymach JV. Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.102828_bib0013","first-page":"2063","article-title":"Combination therapy: a feasibility strategy for CAR-T cell therapy in the treatment of solid tumors","volume":"16","author":"Xu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.tranon.2026.102828_bib0014","first-page":"1671","article-title":"Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates","volume":"12","author":"Jabbarzadeh Kaboli","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"37","key":"10.1016\/j.tranon.2026.102828_bib0015","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1080\/14796694.2024.2409621","article-title":"TROPION-Lung07: phase III study of Dato-DXd + pembrolizumab \u00b1 platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer","volume":"20","author":"Okamoto","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.tranon.2026.102828_bib0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.tranon.2026.102828_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495675","article-title":"Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions","volume":"15","author":"Tong","year":"2024","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.tranon.2026.102828_bib0018","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.3390\/cancers16213622","article-title":"Sacituzumab Govitecan in triple negative breast cancer: a systematic review of clinical trials","volume":"16","author":"Perez-Bermejo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102828_bib0019","article-title":"Real-world clinical outcomes with Sacituzumab Govitecan in metastatic triple-negative breast cancer","author":"Alaklabi","year":"2024","journal-title":"JCO Oncol. Pract."},{"issue":"5","key":"10.1016\/j.tranon.2026.102828_bib0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ijc.28451","article-title":"A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo","volume":"134","author":"Lin","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.102828_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188701","article-title":"Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors","volume":"1877","author":"Akbari","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0022","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/s41467-021-23817-2","article-title":"P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas","volume":"12","author":"Rousso-Noori","year":"2021","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.tranon.2026.102828_bib0023","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.3390\/ijms25158078","article-title":"Targeting the tumor vascular supply to enhance radiation therapy administered in single or clinically relevant fractionated schedules","volume":"25","author":"Horsman","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102828_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114660","article-title":"Recent advances in combretastatin A-4 codrugs for cancer therapy","volume":"241","author":"Guo","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tranon.2026.102828_bib0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/IJN.S283793","article-title":"Galactose modified liposomes for effective Co-delivery of doxorubicin and combretastatin A4","volume":"16","author":"Lian","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64610-7","article-title":"Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy","volume":"14","author":"Sidorenko","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.tranon.2026.102828_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202002094","article-title":"Self-amplifying nanotherapeutic drugs homing to tumors in a manner of chain reaction","volume":"33","author":"Wang","year":"2021","journal-title":"Adv. Mater."},{"issue":"12","key":"10.1016\/j.tranon.2026.102828_bib0028","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2012.151","article-title":"The Trop-2 signalling network in cancer growth","volume":"32","author":"Guerra","year":"2013","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.tranon.2026.102828_bib0029","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.tranon.2026.102828_bib0030","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: tROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102828_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.tranon.2026.102828_bib0032","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ddr.21870","article-title":"Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors","volume":"82","author":"Liao","year":"2021","journal-title":"Drug Dev. Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0033","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab Govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.tranon.2026.102828_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012442","article-title":"Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunother Cancer."},{"key":"10.1016\/j.tranon.2026.102828_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103091","article-title":"Targeted precision strike in extensive-stage small cell lung cancer: current advances and future perspectives for antibody-drug conjugates","volume":"143","author":"Li","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tranon.2026.102828_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105067","article-title":"Antibody-Drug conjugates in urothelial, prostate, and renal cell cancers: a review of current and emerging therapies","volume":"218","author":"Perera","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102828_bib0037","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.62347\/OFER8642","article-title":"Comparative immunohistochemical expression of TROP2 in brain metastatic and primary tumors","volume":"15","author":"Sung","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102828_bib0038","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.breast.2022.10.015","article-title":"Antibody-drug conjugates targeting Trop-2: clinical developments in early breast cancer therapy","volume":"66","author":"Jeong","year":"2022","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.tranon.2026.102828_bib0039","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/ph17050652","article-title":"Progress and innovative combination therapies in Trop-2-targeted ADCs","volume":"17","author":"Jiang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tranon.2026.102828_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-017-0058-5","article-title":"Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management","volume":"5","author":"Grisham","year":"2018","journal-title":"Gynecol. Oncol. Res. Pract."},{"issue":"6","key":"10.1016\/j.tranon.2026.102828_bib0041","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.tranon.2026.102828_bib0042","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1517\/13543780802691068","article-title":"A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)","volume":"18","author":"Siemann","year":"2009","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.tranon.2026.102828_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102828_bib0044","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/10552","article-title":"Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis","volume":"5","author":"Moore","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102828_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.07.005","article-title":"The untold story of IFN-gamma in cancer biology","volume":"31","author":"Kursunel","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.tranon.2026.102828_bib0046","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","article-title":"Applying a clinical lens to animal models of CAR-T cell therapies","volume":"27","author":"Duncan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"18","key":"10.1016\/j.tranon.2026.102828_bib0047","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3390\/cancers16183186","article-title":"Syngeneic mouse models for pre-clinical evaluation of CAR T cells","volume":"16","author":"Ahmed","year":"2024","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.tranon.2026.102828_bib0048","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102828_bib0049","article-title":"The landscape of chimeric antigen receptor T cell therapy in breast cancer: perspectives and outlook","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.tranon.2026.102828_bib0050","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chimeric antigen receptor T-cell efficacy in solid tumors","volume":"26","author":"Fuca","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102828_bib0051","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-025-14402-7","article-title":"From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute","volume":"25","author":"Ebrahim","year":"2025","journal-title":"BMC. Cancer."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:39:10Z","timestamp":1789112350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"alternative-id":["S1936523326001658"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102828","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined treatment of TROP\u20112 targeted CAR-T and vascular disruptor CBP enhances anti\u2011tumor activity in triple\u2011negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102828"}}